Skip to Content

Ceplene Approval Status

  • FDA approved: No
  • Brand name: Ceplene
  • Generic name: histamine dihydrochloride
  • Company: EpiCept Corporation
  • Treatment for: Acute Myeloid Leukemia

Ceplene (histamine dihydrochloride) is intended for use in conjunction with interleukin-2 (IL-2) as a remission maintenance treatment of acute myeloid leukemia.

In August 2010, EpiCept Corporation announced the receipt of a Refusal to File Letter from the U.S. Food and Drug Administration (FDA), with the recommendation for company to conduct an additional confirmatory pivotal trial to establish the therapeutic contribution of Ceplene (histamine dihydrochloride) in combination with interleukin-2 (IL-2) using overall survival as a primary endpoint.

Development Status and FDA Approval Process for Ceplene

Aug 23, 2010EpiCept Corporation Receives Refusal to File Letter from US FDA on Ceplene New Drug Application
Jun 29, 2010EpiCept Files New Drug Application for Ceplene in AML
Feb  2, 2009EpiCept Receives Permission to File Ceplene NDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.